Douglas J. MacMaster
Keine laufenden Positionen mehr
Profil
Douglas J.
MacMaster served as a Senior Vice President at Merck & Co., Inc. from 1961 to 1992.
He was also a Director at Martek Biosciences Corp.
and Neose Technologies, Inc. He received his undergraduate degree from St. Francis Xavier University and his graduate degree from Boston College.
Ehemalige bekannte Positionen von Douglas J. MacMaster
Unternehmen | Position | Ende |
---|---|---|
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Direktor/Vorstandsmitglied | 08.07.2010 |
MERCK & CO., INC. | Corporate Officer/Principal | 01.01.1992 |
Martek Biosciences Corp.
Martek Biosciences Corp. BiotechnologyHealth Technology Martek Biosciences Corp. developed, manufactured and marketed products derived from microalgae. The company was founded in 1985 and was headquartered in Columbia, MD. | Direktor/Vorstandsmitglied | - |
Ausbildung von Douglas J. MacMaster
St. Francis Xavier University | Undergraduate Degree |
Boston College | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
MERCK & CO., INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Health Technology |
Martek Biosciences Corp.
Martek Biosciences Corp. BiotechnologyHealth Technology Martek Biosciences Corp. developed, manufactured and marketed products derived from microalgae. The company was founded in 1985 and was headquartered in Columbia, MD. | Health Technology |